August 8, 2025 — Leads & Copy — Soligenix Inc. (NASDAQ: SNGX) is experiencing increased investor confidence due to advancements in its late-stage therapeutic pipeline, particularly with HyBryte, a therapy for cutaneous T-cell lymphoma (CTCL). HyBryte has received orphan drug designations in the U.S. and Europe, along with FDA Fast Track status.
HyBryte, aimed at treating CTCL, has shown promise as a first-line treatment, with a market estimated at nearly $1 billion globally, 70% of which is in the U.S. A second confirmatory phase 3 study, FLASH2, is underway in the U.S. and Europe, with top-line results expected in 2026.
The therapy uses synthetic hypericin activated by visible light, offering a safer alternative with minimal side effects compared to traditional treatments. Soligenix is also developing other treatments, including SGX302 for psoriasis, SGX942 for inflammatory diseases, and SGX945 for Behçet’s disease. Additionally, the company is working on vaccines like RiVax for ricin toxin and CiVax for COVID-19.
For Corporate Communications, IBN can be reached at Editor@InvestorBrandNetwork.com or 512.354.7000.
Source: Soligenix Inc.
